Literature DB >> 27586202

Ampullary carcinoma is often of mixed or hybrid histologic type: an analysis of reproducibility and clinical relevance of classification as pancreatobiliary versus intestinal in 232 cases.

Michelle D Reid1, Serdar Balci1, Nobuyuki Ohike2, Yue Xue1, Grace E Kim3, Takuma Tajiri4, Bahar Memis1, Ipek Coban5, Anil Dolgun6, Alyssa M Krasinskas1, Olca Basturk7, David A Kooby8, Juan M Sarmiento8, Shishir K Maithel8, Bassel F El-Rayes9, Volkan Adsay1.   

Abstract

Histologic classification of ampullary carcinomas as intestinal versus pancreatobiliary is rapidly becoming a part of management algorithms, with immunohistochemical classification schemes also being devised using this classification scheme as their basis. However, data on the reproducibility and prognostic relevance of this classification system are limited. In this study, five observers independently evaluated 232 resected ampullary carcinomas with invasive component >3 mm. Overall interobserver agreement was 'fair' (κ 0.39; P<0.001) with complete agreement in 23%. Using agreement by 3/5 observers as 'consensus' 40% of cases were classified as 'mixed' pancreatobiliary and intestinal. When observers were asked to provide a final diagnosis based on the predominant pattern in cases initially classified as mixed, there was 'moderate' agreement (κ 0.44; P<0.0001) with 5/5 agreeing in 35%. Cases classified as pancreatobiliary by consensus (including those with pure-pancreatobiliary or mixed-predominantly pancreatobiliary features) had shorter overall (median 41 months) and 5-year survival (38%) than those classified as pure-intestinal/mixed-predominantly intestinal (80 months and 57%, respectively; P=0.026); however, on multivariate analysis this was not independent of established prognostic parameters. Interestingly, when compared with 476 cases of pancreatic ductal adenocarcinomas, the pancreatobiliary-type ampullary carcinomas had better survival (16 versus 41 months, P<0.001), even when matched by size and node status. In conclusion, presumably because of the various cell types comprising the region, ampullary carcinomas frequently show mixed phenotypes and intratumoral heterogeneity, which should be considered when devising management protocols. Caution is especially warranted when applying this histologic classification to biopsies and tissue microarrays. While ampullary carcinomas with more pancreatobiliary morphology have a worse prognosis than intestinal ones this does not appear to be an independent prognostic factor. However, pancreatobiliary-type ampullary carcinomas have a much better prognosis than their pancreatic counterparts.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27586202     DOI: 10.1038/modpathol.2016.124

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  40 in total

1.  Carcinoma of the ampulla of Vater: comparative histologic/immunohistochemical classification and follow-up.

Authors:  Hui Zhou; Nico Schaefer; Martin Wolff; Hans-Peter Fischer
Journal:  Am J Surg Pathol       Date:  2004-07       Impact factor: 6.394

2.  Tumor budding as a strong prognostic indicator in invasive ampullary adenocarcinomas.

Authors:  Nobuyuki Ohike; Ipek Coban; Grace E Kim; Olca Basturk; Takuma Tajiri; Alyssa Krasinskas; Sudeshna Bandyopadhyay; Toshio Morohoshi; Yuki Shimada; David A Kooby; Charles A Staley; Michael Goodman; N Volkan Adsay; Nazmi Volkan Adsay
Journal:  Am J Surg Pathol       Date:  2010-10       Impact factor: 6.394

3.  Expression of MUC1 and MUC2 in ampullary cancer.

Authors:  Toshiyuki Moriya; Wataru Kimura; Ichiro Hirai; Naoki Takasu; Masaomi Mizutani
Journal:  Int J Surg Pathol       Date:  2011-06-23       Impact factor: 1.271

4.  Intra-ampullary papillary-tubular neoplasm (IAPN): characterization of tumoral intraepithelial neoplasia occurring within the ampulla: a clinicopathologic analysis of 82 cases.

Authors:  Nobuyuki Ohike; Grace E Kim; Takuma Tajiri; Alyssa Krasinskas; Olca Basturk; Ipek Coban; Sudeshna Bandyopadhyay; Toshio Morohoshi; Michael Goodman; David A Kooby; Juan M Sarmiento; N Volkan Adsay
Journal:  Am J Surg Pathol       Date:  2010-12       Impact factor: 6.394

5.  Adjuvant chemo-radiotherapy in ampullary cancers.

Authors:  S S Sikora; P Balachandran; K Dimri; N Rastogi; A Kumar; R Saxena; V K Kapoor
Journal:  Eur J Surg Oncol       Date:  2005-03       Impact factor: 4.424

6.  Carcinoma of the ampulla of Vater: morphological and immunophenotypical classification predicts overall survival.

Authors:  Sergio Morini; Giuseppe Perrone; Domenico Borzomati; Bruno Vincenzi; Carla Rabitti; Daniela Righi; Federica Castri; Andrea D Manazza; Daniele Santini; Giuseppe Tonini; Roberto Coppola; Andrea Onetti Muda
Journal:  Pancreas       Date:  2013-01       Impact factor: 3.327

7.  Intestinal-type and pancreatobiliary-type adenocarcinomas: how does ampullary carcinoma differ from other periampullary malignancies?

Authors:  Arne Westgaard; Ewa Pomianowska; Ole Petter F Clausen; Ivar P Gladhaug
Journal:  Ann Surg Oncol       Date:  2012-09-07       Impact factor: 5.344

8.  Factors predictive of survival in ampullary carcinoma.

Authors:  J R Howe; D S Klimstra; R D Moccia; K C Conlon; M F Brennan
Journal:  Ann Surg       Date:  1998-07       Impact factor: 12.969

9.  Intestinal-type of differentiation predicts favourable overall survival: confirmatory clinicopathological analysis of 198 periampullary adenocarcinomas of pancreatic, biliary, ampullary and duodenal origin.

Authors:  Peter Bronsert; Ilona Kohler; Martin Werner; Frank Makowiec; Simon Kuesters; Jens Hoeppner; Ulrich Theodor Hopt; Tobias Keck; Dirk Bausch; Ulrich Friedrich Wellner
Journal:  BMC Cancer       Date:  2013-09-22       Impact factor: 4.430

10.  Ampullary adenocarcinoma - differentiation matters.

Authors:  Peter Schirmacher; Markus W Büchler
Journal:  BMC Cancer       Date:  2008-09-01       Impact factor: 4.430

View more
  11 in total

1.  Immunohistochemical Predictors for Intestinal and Pancreatobiliary Types of Adenocarcinoma of The Ampulla of Vater.

Authors:  João Paulo Lemos da Silveira Santos; Carla Jorge Machado; Eduardo Paulino Junior; João Bernardo Sancio Rocha Rodrigues; Paula Teixeira Vidigal; Vivian Resende
Journal:  J Gastrointest Surg       Date:  2018-05-07       Impact factor: 3.452

2.  Non-ampullary-duodenal carcinomas: clinicopathologic analysis of 47 cases and comparison with ampullary and pancreatic adenocarcinomas.

Authors:  Yue Xue; Alessandro Vanoli; Serdar Balci; Michelle M Reid; Burcu Saka; Pelin Bagci; Bahar Memis; Hyejeong Choi; Nobuyike Ohike; Takuma Tajiri; Takashi Muraki; Brian Quigley; Bassel F El-Rayes; Walid Shaib; David Kooby; Juan Sarmiento; Shishir K Maithel; Jessica H Knight; Michael Goodman; Alyssa M Krasinskas; Volkan Adsay
Journal:  Mod Pathol       Date:  2016-10-14       Impact factor: 7.842

3.  Genome-Derived Classification Signature for Ampullary Adenocarcinoma to Improve Clinical Cancer Care.

Authors:  Saptarshi Chakraborty; Brett L Ecker; Mithat Gonen; Ronglai Shen; William R Jarnagin; Ken Seier; Victoria G Aveson; Vinod P Balachandran; Jeffrey A Drebin; Michael I D'Angelica; T Peter Kingham; Carlie S Sigel; Kevin C Soares; Efsevia Vakiani; Alice C Wei; Rohit Chandwani
Journal:  Clin Cancer Res       Date:  2021-08-25       Impact factor: 12.531

4.  APC mutations are common in adenomas but infrequent in adenocarcinomas of the non-ampullary duodenum.

Authors:  Kenichi Ishizu; Taiki Hashimoto; Tomoaki Naka; Yasushi Yatabe; Motohiro Kojima; Takeshi Kuwata; Satoru Nonaka; Ichiro Oda; Minoru Esaki; Masashi Kudo; Naoto Gotohda; Teruhiko Yoshida; Takaki Yoshikawa; Shigeki Sekine
Journal:  J Gastroenterol       Date:  2021-09-12       Impact factor: 7.527

5.  Endoscopic Papillectomy for Ampullary Adenomas: Different Outcomes in Sporadic Tumors and Those Associated with Familial Adenomatous Polyposis.

Authors:  Paolo Cecinato; Francesca Parmeggiani; Luca Braglia; Gabriele Carlinfante; Ramona Zecchini; Francesco Decembrino; Veronica Iori; Giuliana Sereni; Cristiana Tioli; Maurizio Cavina; Lorenzo Camellini; Francesco Azzolini; Maurizio Ponz de Leon; Romano Sassatelli
Journal:  J Gastrointest Surg       Date:  2020-01-02       Impact factor: 3.452

6.  Surgical treatment of duodenal adenocarcinoma: ampullary vs. non-ampullary, short- and long-term outcomes.

Authors:  Jana Tesarikova; Pavel Skalicky; Daniela Kurfurstova; Hana Svebisova; Ondrej Urban; Premysl Falt; Jana Zapletalova; Dusan Klos; Martin Lovecek
Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub       Date:  2021-05-11       Impact factor: 1.648

7.  Clinical Outcome of Ampullary Carcinoma: Single Cancer Center Experience.

Authors:  Mohammed Al-Jumayli; Amna Batool; Akshay Middiniti; Anwaar Saeed; Weijing Sun; Raed Al-Rajabi; Joaquina Baranda; Sean Kumer; Timothy Schmitt; Anusha Chidharla; Anup Kasi
Journal:  J Oncol       Date:  2019-05-02       Impact factor: 4.375

8.  Tissue microarray-chip featuring computerized immunophenotypical characterization more accurately subtypes ampullary adenocarcinoma than routine histology.

Authors:  Matteo Palmeri; Niccola Funel; Gregorio Di Franco; Niccolò Furbetta; Desirée Gianardi; Simone Guadagni; Matteo Bianchini; Luca E Pollina; Claudio Ricci; Marco Del Chiaro; Giulio Di Candio; Luca Morelli
Journal:  World J Gastroenterol       Date:  2020-11-21       Impact factor: 5.742

9.  Novel method for evaluating the indication for endoscopic papillectomy in patients with ampullary adenocarcinoma.

Authors:  Kenjiro Yamamoto; Takao Itoi; Naoyoshi Nagata; Atsushi Sofuni; Takayoshi Tsuchiya; Kentaro Ishii; Reina Tanaka; Ryosuke Tonozuka; Mitsuyoshi Honjo; Shuntaro Mukai; Yasutsugu Asai; Yukitoshi Matsunami; Hiroshi Yamaguchi; Jun Matsubayashi; Eri Joyama; Yuichi Nagakawa
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

Review 10.  Ampulla of Vater carcinoma: Molecular landscape and clinical implications.

Authors:  Antonio Pea; Giulio Riva; Riccardo Bernasconi; Elisabetta Sereni; Rita Teresa Lawlor; Aldo Scarpa; Claudio Luchini
Journal:  World J Gastrointest Oncol       Date:  2018-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.